Biophysical Society 62nd Annual Meeting | Program Guide

Room 5: Tuesday, February 20 11:30 AM–1:00 PM Malvern Panalytical Integration of Multiple Biophysical Tools to Accelerate the Biotherapeutic Development Process With the myriad of technologies available to assess the biophysical properties of biological materials, it can sometimes be an overwhelm- ing task to identify which properties are most important to assess. This workshop will provide a summary of a typical workflow that can be used to assess the stability indicating properties of biological drug prod- ucts across three different development phases of a drug: • Discovery Phase: From identification of lead candidates to early assessment of developability, the discovery phase is constantly ex- panding the properties that are being measured, while minimizing the volume of drug substance being used. • Formulation Development: Identifying the right candidate in the right formulation is critical to a products success. The need to mea- sure the most relevant properties of the formulation to identify manufacturability is the most important requirement. • Manufacturing: Development of a robust manufacturing process, and early identification of issues associated with process change can keep you ahead of the curve to identify issues before they arise. Speakers Verna Frasca, Field Applications Manager, Biosciences, Malvern Panalytical Clayton Deighan, Field Applications Scientist, Biosciences, Malvern Panalytical Amber Fradkin, Director, Particle Characterization Core Facility, KBI Biopharma

Room 6: Sunday, February 18 10:30 AM–12:00 PM Cellular Dynamics International, a FUJIFILM company Using Human iPSC-Derived Cell-Types in Novel Functional Assays, Disease Modeling, and Drug Discovery The availability of donor-specific induced pluripotent stem (iPS) cells, coupled with gene-editing techniques, is enabling new insights into the molecular basis and mechanisms of human disease. Join us as we describe how Cellular Dynamics’ cryopreserved iPSC-derived cell-types have been used to develop disease models with innate or introduced mutations. 10:30 AM: Dr. Leonard Kaczmarek from Yale University will begin the talks by describing the use of stem cells in understanding mechanisms of ataxias and epilepsy, highlighting human iPSC-derived neurons har- boring mutations in the KCNT1 Slack channel. 11:00 AM: Dr. Kile Mangan from Cellular Dynamics International will fol- low with a talk on utilizing novel functional assays with high-definition multielectrode arrays (HD-MEAs: MaxWell Biosystems) to uncover phenotypic differences in neurons harboring single-nucleotide disease mutations (alpha synuclein A53T Parkinson’s Disease) or in normal control following pharmacological perturbation. 11:30 AM: Recent advances in cardiac tissue engineering have increased significantly cell functional across electrophysiological, Ca2+ handling, and contractility. The third presentation of this session will discuss these advances and provide exemplar laboratory case studies highlighting the increased functionality and experimental implementation. Speakers Leonard Kaczmarek, Professor of Pharmacology and Cellular and Molecular Physiology, Yale University Kile Mangan, Group Leader, Application Development, Cellular Dynamics International, a FUJIFILM company TBD, Cardiomyocyte Bioengineering Applications Specialist

188